What's Happening

Indicated for the treatment of moderate-to-severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Indicated for the adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

Indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome

For the treatment of major depressive disorder, this antidepressant is notable for producing antidepressant results within one week

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Indicated for the treatment of hypertension to lower blood pressure

An NSAID used for the relief of mild to moderate pain or relief in the signs and symptoms of rheumatoid arthritis or osteoarthritis

Indicated for topical treatment of plaque psoriasis

Indicated as an adjunctive therapy for the treatment of partial-onset seizures, this approval is for the first liquid formulation of zonisamide.

Indicated for the treatment of partial-onset seizures.

A biosimilar to Rituxan^® with existing oncology indications, this drug is now approved for the treatment of moderate-to-severe rheumatoid arthritis, in combination with methotrexate.

Approved for its third indication for moderately to severely active Crohn’s disease, in addition to existing indications for moderate-to-severe plaque psoriasis and active psoriatic arthritis.

A steroid-free topical indicated for treatment of plaque psoriasis

Indicated for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, and other assistance with breathing